FAIRR is a founding member of Investor Action on Antimicrobial Resistance, a coalition between FAIRR, the Access to Medicine Foundation, the Principles for Responsible Investment and the UK Government Department of Health and Social Care with the aim of galvanising investor efforts to address global antimicrobial resistance.
The coalition was established in January 2020, and this is its first progress report. This report aims to provide an overview from a “One Health” perspective of the drivers and implications of AMR as an environmental, social and governance (ESG) risk for investors, while showcasing the actions that investor partners are taking through initiatives like IAAMR, which serve as a platform for the collective voice of investors. It will introduce tools and collaborative mechanisms for investors to use in tackling this issue, spotlight learnings from investor partners and highlight upcoming opportunities for greater action from investors and other stakeholders.
The drivers of AMR are interlinked and complex, spanning human health, animal agriculture, and the wider environment. The development of new antibiotics is crucial for combatting rising AMR, yet challenging market conditions have resulted in vast funding gaps for new antibiotics and alternatives. In addition to engaging stakeholders on AMR, investor action is needed to help narrow the funding gap through investments in the space, while tackling the systemic risk of AMR. Investors can adapt to evolving risks and opportunities related to rising AMR, such as the need to diversify business models and product portfolios to safeguard future revenue generation for companies, especially in the food and pharmaceutical sectors.
We would like to thank all the investor partners that have given us their time and insights to prepare the investor case studies for the IAAMR Progress Report. We have valued each of these conversations and we are delighted to showcase the activities and learnings the investors have shared in this report.
The full report is publicly available via the Investor Action on Antimicrobial Resistance website.